Author: Chen, Huixin; Min, Nyo; Ma, Luyao; Mok, Chee-Keng; Chu, Justin Jang Hann
Title: Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection Cord-id: awhngbia Document date: 2020_12_3
ID: awhngbia
Snippet: Chikungunya virus (CHIKV) is a mosquito-borne pathogen that is responsible for numerous large and geographical epidemics, causing millions of cases. However, there is no vaccine or therapeutics against CHIKV infection available. Interferon-alpha (IFN-α) has been shown to produce potent antiviral responses during viral infection. Herein we demonstrated the use of an adenovirus-vectored expressed mouse IFN-α (mDEF201) as a prophylactic and therapeutic treatment against CHIKV in vivo. 6-day-old B
Document: Chikungunya virus (CHIKV) is a mosquito-borne pathogen that is responsible for numerous large and geographical epidemics, causing millions of cases. However, there is no vaccine or therapeutics against CHIKV infection available. Interferon-alpha (IFN-α) has been shown to produce potent antiviral responses during viral infection. Herein we demonstrated the use of an adenovirus-vectored expressed mouse IFN-α (mDEF201) as a prophylactic and therapeutic treatment against CHIKV in vivo. 6-day-old BALB/c mice were pre- or post-treated intranasally with single dose of mDEF201 at 5 x 10(6) PFU per mouse and challenged with lethal dose of CHIKV. Complete survival protection was observed in mice upon a single dose of mDEF201 administration 1 days prior to virus challenge. Viral load in the serum and multiple organs were significantly reduced upon mDEF201 administration in a dose dependent manner as compare with adenovirus 5 vector placebo set. Histological analysis of the mice tissue revealed that mDEF201 could significantly reduce the tissue morphological abnormities, mainly infiltration of immune cells and muscle fibre necrosis caused by CHIKV infection. In addition, administration of mDEF201 at 6 hours post CHIKV challenge also showed promising inhibitory effect against viral replication and dissemination. In conclusion, single-dose of intranasal administration with mDEF201 as a prophylactic or therapeutic agent within 6 hours post CHIKV infection is highly protective against a lethal challenge of CHIKV in the murine model.
Search related documents:
Co phrase search for related documents- acute infection and adenovirus vector: 1, 2, 3, 4, 5
- acute infection and administration time: 1, 2, 3, 4, 5, 6, 7, 8
- acute infection and administration timing: 1, 2, 3, 4
- acute infection and liver brain: 1, 2, 3, 4, 5
- acute infection and liver spleen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute infection and long term complication: 1, 2, 3
- acute infection and low mortality rate: 1, 2, 3, 4, 5
- acute phase and adenovirus vector: 1, 2
- acute phase and administration time: 1, 2, 3
- acute phase and liver brain: 1, 2, 3
- acute phase and liver spleen: 1, 2, 3
- acute phase and long term complication: 1, 2
- adenovirus vector and liver brain: 1
- adenovirus vector and liver spleen: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date